Adaptimmune Therapeutics Plc Прибыль на акцию Q/Q

Что обозначает Прибыль на акцию Q/Q в Adaptimmune Therapeutics Plc?

Прибыль на акцию Q/Q Adaptimmune Therapeutics Plc является -20.00%

Какое определение для Прибыль на акцию Q/Q?



Ежеквартальный темп роста прибыли на акцию, по сравнению с предыдущим кварталом, представляет собой увеличение прибыли на акцию компании за последние 4 квартала по сравнению с показателями за предыдущие 4 квартала.

The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

Прибыль на акцию Q/Q компаний в Health Care сектор на NASDAQ по сравнению с Adaptimmune Therapeutics Plc

Что делает Adaptimmune Therapeutics Plc?

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Компании с прибыль на акцию q/q похож на Adaptimmune Therapeutics Plc